Xolremdi
What Xolremdi is used for
Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- Approved under exceptional circumstances: full data cannot be collected, usually because the disease is very rare.
Key facts
- Brand
- Xolremdi
- Active substance
- mavorixafor
- Disease area
- Primary Immunodeficiency Diseases
- Medicine group
- Immunostimulants
- ATC code
- L03AX24
- Marketing authorisation holder
- Norgine B.V.
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Xolremdi
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Xolremdi used for?
Xolremdi is indicated in patients 12 years of age and older for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.
What is the active substance in Xolremdi?
Xolremdi contains mavorixafor.
Who makes Xolremdi?
The EU marketing authorisation holder is Norgine B.V..
Is Xolremdi an orphan medicine?
Yes. Xolremdi is designated an orphan medicine in the EU, for a rare disease (Primary Immunodeficiency Diseases).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU